← Back to headlines
Morgan Stanley upgrades Vertex Pharmaceuticals following Crinetics acquisition
Investment bank Morgan Stanley has resumed coverage of Vertex Pharmaceuticals with an Overweight rating, citing strategic positioning after the company's recent buyout of Crinetics.
2 Sept, 17:53 — 2 Sept, 17:53
Sources
Showing 1 of 1 sources
